 SAN FRANCISCO, June 04, 2020 GLOBE NEWSWIRE -- 89bio, Inc. ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Lota S. Zoth, CPA to its Board of Directors and as Chair of the Audit Committee. A veteran of the biopharmaceutical industry, Ms. Zoth brings more than 35 years of financial and strategic experience to her role. We are very pleased to have someone of Lotas caliber join 89bios Board of Directors, said Rohan Palekar, CEO of 89bio. 